Celera Corp announced the presentation of data describing a novel mass spectrometry-based approach to identify and validate circulating protein biomarkers that detect non-small cell lung cancer (NSCLC).
A key outcome of the study was the assembly of an immunoassay test for a panel of 6 biomarkers that detected lung cancer with 94% sensitivity and 93% specificity in a blinded analysis. In additioCelera Presents Data Describing an Immunodiagnostic Assay to Detect Lung Cancer from Blood Serum
n to detecting all stages of lung cancer studied and all major histological subtypes, the panel also accurately distinguished malignant cases from benign lung disease.
“We believe these findings present an important development in our efforts to develop a robust method to detect lung cancer using a simple blood test,” said Steve Ruben, PhD, VP of Proteomics at Celera. “To this end, we have employed a novel mass spectrometry-based approach to finding biomarkers based on discovery from tumor tissues and tumor cell lines rather than from serum directly. This has allowed us to identify a collection of biomarkers which we have subsequently shown to be elevated in the blood of non-small cell lung cancer patients relative to appropriate controls.”
“We believe a test with this accuracy would have an opportunity to impact non-small cell lung cancer patient outcomes at many levels,” said Thomas White, PhD, Chief Scientific Officer at Celera.
“For example, a test that precedes radiographic methods of detection, such as helical Computed Tomography, could reduce the number of patients requiring subsequent CT scans substantially, potentially reducing expensive workup and minimizing the morbidities associated with additional diagnostic procedures following a positive CT scan. We’re exploring the commercial opportunities for this program as we continue to validate these findings in a clinical setting.”
Source: Celera
